Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131479 · ClinicalTrials.gov registry record · Phase 2
Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03131479 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 53 participants.
The verdict
NCT03131479, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this trial was to evaluate whether the study drug, LIK066, causes glucose excretion in urine in patients with varying degrees of decreased kidney function and in subjects with normal kidney function. Blood samples were collected to measure the concentrations of LIK066 and to study the pharmacokinetics of LIK066. Pharmacokinetics is meant to study how LIK066 is absorbed, distributed and eliminated, in other words what the body does to the drug. The results of this study may be used to help determine whether LIK066 can be used to treat people with reduced kidney function and the proper dosing regimen.
Interventions
- DRUG LIK066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-04-28 |
| Est. Completion | 2018-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03131479
The ClinicalTrials.gov registry entry for NCT03131479 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LIK066 is the first listed.
NCT03131479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03131479 about?
NCT03131479 is a clinical study titled "Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.". The purpose of this trial was to evaluate whether the study drug, LIK066, causes glucose excretion in urine in patients with varying degrees of decreased kidney function and in subjects with normal kidney function. Blood samples were collected to measure the concentrations of LIK066 and to study the...
What is the current status of trial NCT03131479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-04-28. Estimated completion is 2018-01-16.
What interventions are being tested in trial NCT03131479?
The interventions under investigation include: LIK066 (DRUG).
Who is sponsoring clinical trial NCT03131479?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.